



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**03.03.2021 Bulletin 2021/09**

(45) Date of publication and mention  
of the grant of the patent:  
**18.11.2020 Bulletin 2020/47**

(21) Application number: **17764971.2**

(22) Date of filing: **29.08.2017**

(51) Int Cl.:  
**C07D 265/14<sup>(2006.01)</sup> A61K 31/537<sup>(2006.01)</sup>**  
**A61P 25/24<sup>(2006.01)</sup>**

(86) International application number:  
**PCT/US2017/049129**

(87) International publication number:  
**WO 2018/044896 (08.03.2018 Gazette 2018/10)**

(54) **HYDROXYNORKETAMINE DERIVATIVES FOR THE TREATMENT OF DISORDERS**  
HYDROXYNORKETAMINDERIVATE ZUR BEHANDLUNG VON ERKRANKUNGEN  
DÉRIVÉS D'HYDROXYNORKÉTAMINE POUR LE TRAITEMENT DES MALADIES

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **31.08.2016 US 201662382132 P**

(43) Date of publication of application:  
**10.07.2019 Bulletin 2019/28**

(73) Proprietor: **Dart NeuroScience, LLC**  
**Dallas, TX 75219 (US)**

(72) Inventors:  
• **GOMEZ, Laurent**  
**Dallas, TX 75219 (US)**  
• **MASSARI, Mark, Eben**  
**Texas, TX 75219 (US)**

(74) Representative: **McGuire, Gillian Margaret**  
**Carpmaels & Ransford LLP**  
**One Southampton Row**  
**London WC1B 5HA (GB)**

(56) References cited:  
**WO-A1-2004/045601**

- **PANOS ZANOS ET AL: "NMDAR inhibition-independent antidepressant actions of ketamine metabolites", NATURE, vol. 533, no. 7604, 4 May 2016 (2016-05-04), pages 481-486, XP55368059, ISSN: 0028-0836, DOI: 10.1038/nature17998 cited in the application**
- **MOADDEL R ET AL: "A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome", TALANTA, ELSEVIER, AMSTERDAM, NL, vol. 82, no. 5, 15 October 2010 (2010-10-15), pages 1892-1904, XP027338855, ISSN: 0039-9140 [retrieved on 2010-08-13] cited in the application**
- **J. D. ADAMS ET AL: "Studies on the biotransformation of ketamine 1-Identification of metabolites produced in vitro from rat liver microsomal preparations", BIOLOGICAL MASS SPECTROMETRY, vol. 8, no. 11, 1 November 1981 (1981-11-01), pages 527-538, XP55048408, ISSN: 1052-9306, DOI: 10.1002/bms.1200081103**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **PATRICK J. MORRIS ET AL: "-aspartate (NMDA) Receptor Activity of Ketamine Metabolites", ORGANIC LETTERS , 14(23), 6012-6015 CODEN: ORLEF7; ISSN: 1523-7052, vol. 19, no. 17, 22 August 2017 (2017-08-22), pages 4572-4575, XP055410503, ISSN: 1523-7060, DOI: 10.1021/acs.orglett.7b02177**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification